Navigation Links
Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
Date:1/24/2008

Conference Call and Webcast Scheduled for Tuesday, February 5

SAN DIEGO, Jan. 24 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its fourth quarter and year-end 2007 financial results after the Nasdaq market closes on Tuesday, February 5, 2008. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Tuesday afternoon, February 5, 2008 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Participants can access the live conference call by dialing 800-862-9098, (US) or 785-424-1051 (International) using the conference ID: 7NBIX2. The call can also be accessed via the webcast through the Company's website at http://www.neurocrine.com

If you are unable to attend the Webcast and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at (858) 617-7600. A replay of the Conference Call will be available approximately one hour after the conclusion of the call by dialing 1-800-723-0520 (US) or 402-220-2653 (International) using the conference ID: 7NBIX2. The call will be archived for two weeks.

Neurocrine Biosciences, Inc. is a product-based biopharmaceutical company focused on neurological and endocrine diseases and disorders. The product candidates address some of the largest pharmaceutical markets in the world including insomnia, anxiety, depression, irritable bowel syndrome, endometriosis and CNS related disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the Internet at http://www.neurocrine.com


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
2. Neurocrine Announces Work Force Restructuring
3. Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA
4. Neurocrine Biosciences Announces Conference Call and Webcast to Provide Indiplon Update
5. Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2007 Financial Results
7. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
8. Neurocrine Biosciences to Present at the A.G. Edwards Annual Emerging Growth Conference
9. Neurocrine Biosciences to Present at the Bear Stearns Healthcare Conference
10. Neurocrine Biosciences to Present at the Thomas Weisel Partners Healthcare Conference
11. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... (PRWEB) , ... May 22, 2017 , ... ... joined with other leaders of the Maryland Biohealth community in developing and issuing ... recognized Top 3 U.S. BioHealth Innovation Hub by 2023. , ...
(Date:5/19/2017)... ... May 19, 2017 , ... In response to the strong base ... Medical Systems, Inc. announces the release of their Gait Trainer 3 with an Integrated ... a biomedical system to aid in rehabilitating individuals with cerebral palsy, traumatic brain injury, ...
(Date:5/18/2017)... ... 2017 , ... Clinical Supplies Management (“CSM”), a Great Point Partners II (“GPP”) ... CSM has doubled in size over the past six months with the acquisition ... Roger Gasper joins CSM as Chief Financial Officer. Roger has over 25 years ...
(Date:5/18/2017)... ... May 17, 2017 , ... ... process optimization firm for the life sciences and healthcare industries, is honored that ... Traceability for Medical Devices conference in Brussels, Belgium. , Crowley played a crucial ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...
Breaking Biology News(10 mins):